Reading BIOA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIOA free→Reading BIOA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIOA free→QuarterlyIQ Insights · BIOA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 8, 2026, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exch…
and this Item 7.01, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”). The information contained in Item 2.02, this Item 7.01, and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any…
Entry into a Material Definitive Agreement. On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.000…
Results of Operations and Financial Condition. On November 6, 2025, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…
Results of Operations and Financial Condition. On August 6, 2025, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ E…
Other Events. On June 4, 2025, the Company announced, in its corporate presentation, updates related to anticipated timing of certain milestones, including the following: NLRP3 Program Updates • IND submission and initiation of a Phase 1 SAD/MAD trial planned for mid-2025, with initial SAD data anticipated by end of year . • Full Phase 1 SAD/MAD data anticipated mid -2026 • Obesity proof-of-concept data anticipated in the second half of 2026 APJ Agonist Program Updates • The Company is contin…
Results of Operations and Financial Condition. On May 6, 2025, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exch…
Results of Operations and Financial Condition. On March 20, 2025, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchang…
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.